Publications by authors named "M Lizasoain"
Article Synopsis
- * A retrospective study from 2011 to 2020 documented 51 cases of leishmaniasis, revealing a significantly higher incidence in the railway-connected districts of Villaverde and Usera compared to Carabanchel.
- * Researchers suggest that the rail connection to the outbreak area may explain the increased incidence in Villaverde and Usera, despite no demographic or risk factor differences among the districts.
Epidemiology and risk factors associated to bacterial resistance in solid organ cancer (SOC) patients has been barely described. This retrospective monocentric study analyzed clinical variables in SOC patients who developed bacteremia between 1 January 2019 and 31 December 2022. We described rates of bacterial resistance in Gram negative bacteria (80.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the prevalence of Trypanosoma cruzi infection (Chagas disease) among pregnant migrants in Madrid, focusing on their countries of origin and the effectiveness of screening methods.
- Conducted across eight hospitals between 2011 and 2016, it found that out of 149,470 deliveries, only 11,048 pregnant women were screened, with a significant majority being from Bolivia and a high prevalence of infection among those screened.
- Results highlighted a 47% average screening coverage across hospitals, showing a stark contrast between those with universal screening (73% coverage) versus selective screening (10% coverage), providing essential insights for health policymakers.
Article Synopsis
- The study aimed to determine whether OXA-48 carbapenemase production affects the outcome of Klebsiella pneumoniae infections after adjusting for clinical factors.
- It involved comparing 117 cases of infections caused by OXA-48-producing strains with 117 cases from non-OXA-48 strains, focusing on clinical cure rates and mortality.
- Results indicated that OXA-48 strains were linked to significantly lower clinical cure rates and higher 30-day mortality, establishing OXA-48 production as an independent risk factor for poor outcomes in infections.
Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID-19) is still a relevant cause of morbidity among immunocompromised patients. Despite the proven efficacy of nirmatrelvir/ritonavir (NMV/r), concerns remain regarding the potential for drug-to-drug interactions (DDIs) and the safety in this at-risk population. We aimed to evaluate the clinical outcomes of immunocompromised patients treated with NMV/r, as well as the occurrence of DDIs and treatment-emergent adverse events (TEAEs).
View Article and Find Full Text PDF